ReviewOpen forum infectious diseases2019
Prevalence of Anti-HCV Antibody Among the General Population in Mainland China Between 1991 and 2015: A Systematic Review and Meta-analysis.
Review in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Seroprevalence of Hepatitis C Viral Infection in Ethiopia: A Systematic Review and Meta-Analysis.TheScientificWorldJournal · 2021Pooled it
- Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial.Nature medicine · 2023Trial
- Article
- The three-decade trajectory of hepatitis C burden among women of reproductive age in China: a retrospective and predictive study.Virology journal · 2026Article
- Over one-third of cancer cases and two-fifths of cancer deaths in southern China are preventable: Insights from the latest representative population-based cancer registry data and risk factor survey.International journal of cancer · 2026Article
- Hospital-based micro-elimination of hepatitis C virus: improving timely case identification and linkage to care in a tertiary hospital.Frontiers in medicine · 2026Article
- HCV screening among surgical patients in a tertiary hospital of Northern China.BMC gastroenterology · 2025Article
- Pathway to hepatitis C elimination: insights from a large tertiary hospital in South China.Annals of medicine · 2025Article
- The impact of HBV, HCV, or syphilis infections on embryo and pregnancy outcomes in couples undergoing IVF treatment: a matched cohort study.Human reproduction open · 2025Article
- Hepatitis C virus subtype diversity and transmission clusters characteristics among drug users in Zhuhai, South China.BMC infectious diseases · 2024Article
- Anti-hepatitis C antibody carriage and risk of liver impairment in rural-Cameroon: adapting the control of hepatocellular carcinoma for resource-limited settings.BMC infectious diseases · 2023Observational
- Hepatitis C Knowledge and Self-Reported Testing Behavior in the General Population in China: Online Cross-Sectional Survey.JMIR public health and surveillance · 2023Article
- Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment.BMC gastroenterology · 2023Article
- Distribution of hepatitis C virus genotype and subtype between Mongolian and Han in Inner Mongolia.Medicine · 2022Article
- Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study.Infectious diseases of poverty · 2022Observational
- Impact of prothrombin and factor V Leiden mutations on the progression of fibrosis in patients with chronic hepatitis C.PloS one · 2022Article
- Prevalence of HCV Infection Among Hemodialysis Patients in Lanzhou of Northwestern China.Infection and drug resistance · 2022Article
- Prevalence, diagnosis, and treatment of hepatitis C in Mainland China.Global health & medicine · 2021Review
- Alcohol drinking and risks of liver cancer and non-neoplastic chronic liver diseases in China: a 10-year prospective study of 0.5 million adults.BMC medicine · 2021Article
- Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our study aims to estimate the burden of hepatitis C virus (HCV) infection among the general population in Mainland China. We searched 4 databases for studies of the prevalence of anti-HCV antibody among the general population. Studies that met the selection criteria were included in the meta-analysis. Ninety-four studies with 10729 929 individuals were finally included. Overall, the prevalence of anti-HCV antibody among the general population in Mainland China is 0.91% (95% confidence interval, 0.81%-1.03%). The prevalence rates of anti-HCV antibody were geographically different, with a range of 0.32%-6.51%, and the East and South of China had a relatively lower prevalence. The prevalence of anti-HCV antibody increased successively from 0.16% to 3.95% with advancing age. It was noteworthy that the prevalence of anti-HCV antibody decreased continuously from 2.09% to 0.45% during 1991-2010, whereas it increased to 0.58% during 2011-2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.